| Eligibility |
Inclusion Criteria:
- Patients must be enrolled or agree to consent to the companion genomic profiling study
MSKCC IRB# 12-245 Part A. Results are not required prior to initiating treatment on
protocol, unless patients do not have other test results by IHC or FISH confirming
HER2 overexpression.
- Patients must have recurrent or persistent HER2 overexpressing endometrial cancer or
endometrial carcinosarcoma. HER2 overexpression is defined as 3+ by IHC or 2+ with
gene amplification by FISH (HER2/CEP17 ratio = 2) or HER2 amplified (fold change = 2)
on MSK IMPACT.
- Histologic documentation of diagnosis of endometrial carcinoma or carcinosarcoma is
required.
- Age = 18 years
- Patients must have had at least one but no more than two prior chemotherapeutic
regimens for management of endometrial carcinoma (including neo-adjuvant and/or
adjuvant chemotherapy). Initial treatment may include chemotherapy, chemotherapy and
radiation therapy, and/or consolidation/maintenance therapy. Chemotherapy administered
in conjunction with primary radiation as a radio-sensitizer WILL be counted as a
systemic chemotherapy regimen. Prior hormonal therapy will not count as a prior
regimen. Prior treatment with trastuzumab is allowed.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- LVEF = 50% on baseline screening ECHO.
- Resolution of adverse effects of recent surgery, radiotherapy, or chemotherapy to
Grade = 1 prior to first study treatment (with the exception of alopecia or clinically
insignificant laboratory values).
- Patients must have measurable disease. Measurable disease is defined by RECIST
(version 1.1). Measurable disease is defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded). Each
non-nodal lesion must be 10 mm when measured by CT, MRI or caliper measurement by
clinical exam; or 20 mm when measured by chest x-ray. Lymph nodes must be = 15 mm in
short axis when measured by CT or MRI.
- No active infection requiring antibiotics (with the exception of uncomplicated urinary
tract infection).
- All patients must consent to mandatory pre-treatment and post-treatment core needle
biopsies.
- Patients must have adequate hematological, liver, cardiac and kidney function within
14 days prior to first treatment:
1. Absolute neutrophil count (ANC) = 1.5 x 10^9/L (> 1500 per mm^3)
2. Platelet = 100 X 109/L (>100,000 per mm^3)
3. Hemoglobin = 8.0 g/dL
4. Serum bilirubin = 1.5 x institutional upper limit of normal (ULN). (Unless
Gilbert's Syndrome, for which Bilirubin = 3 x institutional upper limit of normal
(ULN), without concurrent clinically significant liver disease) AST (SGOT)/ALT
(SGPT) = 3 x institutional upper limit of normal (ULN) unless liver metastases
are present, in which case it must be = 5x ULN.
5. Serum creatinine = 1.5 x institutional upper limit of normal (ULN).
- For patients of childbearing potential, agreement to use two effective forms of
contraception (e.g., surgical sterilization, a reliable barrier method, birth control
pills, or contraceptive hormone implants) and to continue its use for the duration of
the study and for 12 weeks after the last ZW25 dose.
- Agree to practice total abstinence when this is in line with the preferred and usual
lifestyle of the subject.
1. A woman is considered to be of childbearing potential unless 1 of the following
applies: She is considered to be permanently sterile. Permanent sterilization
methods include hysterectomy, bilateral salpingectomy, tubal ligation, and
bilateral oophorectomy.
2. She is postmenopausal, defined as no menses for 12 months without an alternative
medical cause. A high follicle-stimulating hormone (FSH) level consistently in
the postmenopausal range (30 mIU/mL or higher) may be used to confirm a
postmenopausal state in women not using hormonal contraception or hormonal
replacement therapy; however, in the absence of 12 months of amenorrhea, a single
FSH measurement is insufficient to confirm a postmenopausal state.
3. Female patients of childbearing potential must have a negative serum pregnancy
test result less than 3 day prior to administration of the first dose of study
treatment.
Patients or their legally authorized representative (LAR) must be willing and able to sign
the informed consent form, and to adhere to the study visit schedule and other protocol
requirements.
Exclusion Criteria:
- Women who are pregnant or lactating or women of childbearing potential (WCBP) not
protected by highly-effective contraceptive methods.
- > Grade 1 peripheral neuropathy.
- History of hemorrhagic or ischemic stroke within the prior six months.
- History of NYHA Class II-IV heart failure, no serious arrhythmia.
- History of MI or unstable angina within 6 months of study initiation.
- Patients with a lifetime cumulative dose of anthracycline >300 mg/m2 or who have
received anthracycline treatment within 90 days of the expected first dose of ZW25 are
not eligible for treatment.
- Prior hypersensitivity to monoclonal antibodies.
- Active hepatitis B or hepatitis C infection. Patients with previously resolved
hepatitis B infection are eligible. Presence of positive test results for hepatitis B
infection who have resolved the infection (defined by positive for HB surface antibody
(anti-HBs) and polymerase chain reaction (PCR) assay is negative for HBV DNA are
eligible. Patients positive for HCV antibody are eligible only if testing for HCV RNA
is negative.
- Known HIV infection.
- Current severe, uncontrolled systemic disease (e.g., clinically significant
cardiovascular, pulmonary, or metabolic disease).
- Major surgical procedure or significant traumatic injury within 28 days prior to Day 1
or anticipation of the need for major surgery during the course of study treatment.
- Known untreated or active central nervous system (CNS) metastases (progressing or
requiring anticonvulsants or corticosteroids for symptomatic control) leptomeningeal
carcinomatosis.
Patients with a history of treated CNS metastases are eligible, provided that they meet all
of the following criteria:
1. Presence of measurable disease outside the CNS
2. No radiographic evidence of worsening upon the completion of CNSdirected therapy and
no evidence of interim progression between the completion of CNS-directed therapy and
the screening radiographic study
3. No history of intracranial hemorrhage or spinal cord hemorrhage
4. No ongoing requirement for dexamethasone as therapy for CNS disease (anticonvulsants
at a stable dose are allowed)
5. Absence of leptomeningeal disease
- Inability to comply with study and follow-up procedures.
- Known allergy or hypersensitivity to the components of ZW25 formulation.
- Any other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding that, in the investigator's opinion, gives reasonable
suspicion of a disease or condition that contraindicates the use of an
investigational drug or that may affect the interpretation of the results or
render the patient at high risk from treatment complications.
- Active or history of inflammatory bowel disease (IBD)
- Severe infections within 4 weeks prior to initiation of study drug treatment,
including but not limited to hospitalization for complications of infection,
bacteremia, or severe pneumonia.
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to
initiation of study treatment. Patients receiving prophylactic antibiotics (e.g.,
for prevention of urinary tract infection or to prevent chronic obstructive
pulmonary disease exacerbation) are eligible for the study. Patients receiving
antibiotic treatment for urinary tract infection are also eligible.
- Administration of a live attenuated vaccine within 4 weeks prior to initiation of
study treatment or anticipated need for such a vaccine during study. Patients
must agree not to receive live, attenuated influenza vaccine (e.g., Flumist®)
within 4 weeks prior to treatment.)
- Participation in another clinical study with receipt of an investigational
product during the last 4 weeks.
- History of another primary malignancy except for:
a. Malignancy treated with curative intent and with no known active disease = 2 years
before the first dose of study drug and of low potential risk for recurrence. b. Adequately
treated non-melanoma skin cancer or lentigo maligna without evidence of disease. c.
Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in
situ). d. Adequately treated stage 1 breast cancer.
- Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted
therapy, biologic therapy, tumor embolization, monoclonal antibodies) < 21 days prior
to the first dose of study drug. Receipt of the last dose of hormonal therapy within <
7 days prior to the first dose of study drug.
- Any prior radiation therapy must be discontinued at least four weeks prior to
registration.
- QT interval corrected for heart rate (QTc) = 470 ms on screening electrocardiograms
(ECG) using QTC Federica.
- History of small or large bowel obstruction within 3 months of registration, including
subjects with palliative gastric drainage catheters. Subjects with palliative
diverting ileostomy or colostomy are allowed if they have been symptom free for more
than 3 months.
- Subjects with refractory ascites, defined as ascites needing drainage catheter or
therapeutic paracentesis more often than every 4 weeks.
- Ongoing bowel perforation or presence of bowel fistula or abscess within 3 months of
registration.
|
